Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7247669 · 2 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| Low dose every three weeks (Q3W) | EXPERIMENTAL | Participants will receive RO7247669 Q3W until loss of clinical benefit, unacceptable toxicity, or a maximum of 24 months. |
| High dose Q3W | EXPERIMENTAL | Participants will receive RO7247669 Q3W until loss of clinical benefit, unacceptable toxicity, or a maximum of 24 months. |
| Part A: Single-Agent Dose Escalation | EXPERIMENTAL | Participants will receive RO7247669 every 2 weeks (Q2W) or every 3 weeks (Q3W) up to the maximum tolerated dose (MTD) until disease progression, unacceptable drug toxicity, or withdrawal of consent, for up to 24 months. |
| Part B: Tumor Specific Expansion Cohorts | EXPERIMENTAL | Participants with selected solid tumor indications will receive RO7247669 at a dose derived from Part A until disease progression, unacceptable drug toxicity, or withdrawal of consent, for up to 24 months. |
| Name | Type | Description |
|---|---|---|
| RO7247669 | DRUG | Participants will receive intravenous (IV) RO7247669 Q3W |
Inclusion Criteria: * Histologically confirmed unresectable or metastatic melanoma, per the American Joint Committee on Cancer (AJCC) staging system (unresectable Stage III or Stage IV) * Radiologically measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Eas...
Top 20 of 51 competitors
RO7247669 is an investigational bispecific antibody being studied for the treatment of solid tumors and melanoma. It is currently in clinical development for advanced or metastatic solid tumors, including non-small cell lung cancer and esophageal squamous cell carcinoma, as well as for previously untreated unresectable or metastatic melanoma.
RO7247669 targets PD-1 and LAG-3, as it is a PD1-LAG3 bispecific antibody. By binding to both of these immune checkpoint proteins, it is designed to modulate the immune response against tumor cells.
RO7247669 is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy in oncology indications.
RO7247669 is in Phase 2 clinical development. It has completed a Phase 1 dose escalation study and a Phase 2 study in melanoma. The drug is investigational and has not been approved by regulatory authorities.
RO7247669 has been studied in two clinical trials. NCT04140500 is a Phase 1 dose escalation study in patients with advanced or metastatic solid tumors. NCT05419388 is a Phase 2 study in participants with previously untreated unresectable or metastatic melanoma.
Yes, RO7247669 is a PD1-LAG3 bispecific antibody. It is designed to target both PD-1 and LAG-3, and it is being investigated for its potential role in treating solid tumors and melanoma.